| Field | Row 1 |
|---|---|
| adsh | 0001558370-25-006964 |
| cik | 75252 |
| name | OWENS & MINOR INC/VA/ |
| sic | 5047 |
| countryba | US |
| stprba | VA |
| cityba | GLEN ALLEN |
| zipba | 23060 |
| bas1 | 10900 NUCKOLS ROAD |
| bas2 | SUITE 400 |
| baph | 8047237000 |
| countryma | US |
| stprma | VA |
| cityma | GLEN ALLEN |
| zipma | 23060 |
| mas1 | 10900 NUCKOLS ROAD |
| mas2 | SUITE 400 |
| countryinc | US |
| stprinc | VA |
| ein | 541701843 |
| former | O&M HOLDING INC |
| changed | 19940504 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250508 |
| accepted | 2025-05-08 16:06:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | omi-20250331x10q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-006964 | 20231231 | Accounts Payable Current | 23000000.0000 | USD | 0 | us-gaap/2023 | Restatement= Revision Of Prior Period Error Correction Adjustment; | ||
| 0001558370-25-006964 | 20241231 | Accounts Payable Current | 1228691000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Acquisition Related Charges And Intangible Amortization | 29674000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20241231 | Assets | 4606774000.0000 | USD | 0 | us-gaap/2023 | Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Assets | 2166951000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Assets Current | 2206198000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Cash And Cash Equivalents At Carrying Value | 59436000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20231231 | Common Stock Shares Outstanding | 76546000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20250331 | Common Stock Shares Outstanding | 77220000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20240331 | Comprehensive Income Net Of Tax | -33505000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Depreciation Depletion And Amortization | 74095000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Depreciation Depletion And Amortization | 35334000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20240331 | Gain Loss On Sale Of Property Plant Equipment | 15619000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Income Tax Expense Benefit | -5226000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Increase Decrease In Other Operating Capital Net | 76476000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Liabilities Current | 1852052000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Net Income Loss | -21886000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20250331 | Operating Income Loss | 1153000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Other Assets Noncurrent | 140158000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | -1619000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -13266000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 5133000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006964 | 20240331 | Payments For Repurchase Of Common Stock | 0.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 45997000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Proceeds From Long Term Lines Of Credit | 0.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 520332000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2612680000.0000 | USD | 1 | us-gaap/2023 | Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1958164000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Selling General And Administrative Expense | 462352000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Share Based Compensation | 1407000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | 7663000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | -43437000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | 154398000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | 570979000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Value Of Shares Adjusted For Share Based Compensation | -195000.0000 | USD | 1 | 0001558370-25-006964 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20240331 | Acquisition Related Charges And Intangible Amortization | 20313000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20240331 | Acquisition Related Charges And Intangible Amortization | 20313000.0000 | USD | 1 | 0001558370-25-006964 | Consolidation Items= Material Reconciling Items; | ||
| 0001558370-25-006964 | 20241231 | Additional Paid In Capital Common Stock | 454151000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Assets | 2429513000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2023 | ||||
| 0001558370-25-006964 | 20240331 | Common Stock Shares Outstanding | 76449000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20250331 | Comprehensive Income Net Of Tax | -19849000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Cost Of Revenue | 1738900000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Deferred Income Taxes And Tax Credits | -3659000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Deferred Income Taxes And Tax Credits | -6240000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Deferred Income Tax Liabilities Net | 16307000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Depreciation Depletion And Amortization | 11547000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20250331 | Income Tax Expense Benefit | -10092000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Increase Decrease In Accounts Payable Trade | 157668000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Intangible Assets Net Excluding Goodwill | 89000000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20241231 | Liabilities And Stockholders Equity | 4656156000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Liabilities And Stockholders Equity | 4856424000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Liabilities Current | 1960215000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Net Cash Provided By Used In Financing Activities | 92778000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Net Cash Provided By Used In Investing Activities | -1870000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Net Cash Provided By Used In Investing Activities | -48200000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Nonoperating Income Expense | -1239000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Operating Income Loss | 11486000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Operating Income Loss | 60141000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Other Assets Current | 149515000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Assets Noncurrent | 129766000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 795000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -1619000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001558370-25-006964 | 20231231 | Other Liabilities Noncurrent | 500000.0000 | USD | 0 | us-gaap/2023 | Restatement= Revision Of Prior Period Error Correction Adjustment; | ||
| 0001558370-25-006964 | 20240331 | Other Operating Income Expense Net | -551000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Operating Income Expense Net | -2101000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Proceeds From Accounts Receivable Financing Agreement | 0.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20240331 | Repayments Of Accounts Receivable Financing Agreement | 139300000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20241231 | Retained Earnings Accumulated Deficit | 27159000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Share Based Compensation | 6928000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Shares Adjusted For Share Based Compensation | 97000.0000 | shares | 1 | 0001558370-25-006964 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | 945304000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | 152897000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | 154439000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20240331 | Value Of Shares Adjusted For Share Based Compensation | 4207000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20250331 | Accounts And Notes Receivable Net | 580175000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Accounts And Notes Receivable Net | 690241000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -44211000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Additional Paid In Capital Common Stock | 459731000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Additions To Property And Equipment Exclude Purchases Remain Unpaid | 69368000.0000 | USD | 0 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20241231 | Allowance For Doubtful Accounts Receivable Current | 6238000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Allowance For Doubtful Accounts Receivable Current | 6371000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Business Exit Costs1 | 31226000.0000 | USD | 1 | us-gaap/2023 | Consolidation Items= Material Reconciling Items; | ||
| 0001558370-25-006964 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 272924000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 59436000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Employee Related Liabilities Current | 87388000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Goodwill | 1331281000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Goodwill | 103141000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20250331 | Gross Profit | 526013000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Increase Decrease In Operating Lease Right Of Use Assets And Operating Lease Liability | -1139000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20241231 | Intangible Assets Net Excluding Goodwill | 210000000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20241231 | Intangible Assets Net Excluding Goodwill | 21352000.0000 | USD | 0 | us-gaap/2023 | Finite Lived Intangible Assets By Major Class= Other Intangible Assets; | ||
| 0001558370-25-006964 | 20250331 | Intangible Assets Net Excluding Goodwill | 156633000.0000 | USD | 0 | us-gaap/2023 | Finite Lived Intangible Assets By Major Class= Customer Relationships; | ||
| 0001558370-25-006964 | 20250331 | Liabilities | 4285445000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Long Term Debt Current | 49947000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Net Income Loss | -24982000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Operating Income Loss | 57365000.0000 | USD | 1 | us-gaap/2023 | Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Operating Income Loss | 124000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Assets Current | 158048000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 235000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 1412000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001558370-25-006964 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 55697000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Repayments Of Long Term Lines Of Credit | 679484000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Retained Earnings Accumulated Deficit | 1020000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Selling General And Administrative Expense | 477613000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | -31818000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | 916006000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | 367959000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | 454151000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006964 | 20250331 | Accounts Payable Current | 1380736000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 565119000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Additions To Property And Equipment Exclude Purchases Remain Unpaid | 81085000.0000 | USD | 0 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20241231 | Assets | 2177261000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Assets Current | 2021017000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -2130000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 10054000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Common Stock Par Or Stated Value Per Share | 2.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Common Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Cost Of Revenue | 2077151000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Deferred Income Tax Liabilities Net | 22456000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Employee Related Liabilities Current | 151039000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Gain Loss On Sale Of Property Plant Equipment | 5353000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Increase Decrease In Operating Lease Right Of Use Assets And Operating Lease Liability | -14452000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20240331 | Interest Paid Net | 18211000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Long Term Debt And Capital Lease Obligations | 1897515000.0000 | USD | 0 | us-gaap/2023 | Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001558370-25-006964 | 20241231 | Long Term Debt Current | 45549000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Net Cash Provided By Used In Operating Activities | -52962000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Net Cash Provided By Used In Operating Activities | -35066000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -11619000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006964 | 20241231 | Other Liabilities Current | 426773000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Noncash Income Expense | -3168000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Operating Income Expense Net | -370000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Payments For Proceeds From Other Investing Activities | 410000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Payments For Repurchase Of Common Stock | 1503000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Proceeds From Payments For Other Financing Activities | -3219000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Repayments Of Accounts Receivable Financing Agreement | 0.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20240331 | Repayments Of Long Term Debt | 4625000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Retained Earnings Accumulated Deficit | 21000000.0000 | USD | 0 | us-gaap/2023 | Restatement= Revision Of Prior Period Error Correction Adjustment; | ||
| 0001558370-25-006964 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2550610000.0000 | USD | 1 | us-gaap/2023 | Geographical= U S; | ||
| 0001558370-25-006964 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 673884000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2580716000.0000 | USD | 1 | us-gaap/2023 | Geographical= U S; | ||
| 0001558370-25-006964 | 20240331 | Selling General And Administrative Expense | 224081000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | -5115000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | 153092000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | -49344000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | -42142000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | 459731000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006964 | 20250331 | Stock Issued During Period Value Share Based Compensation | 387000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -49344000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Assets | 4856424000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Business Exit Costs1 | 27356000.0000 | USD | 1 | us-gaap/2023 | Consolidation Items= Material Reconciling Items; | ||
| 0001558370-25-006964 | 20250331 | Business Exit Costs1 | 31226000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Cash And Cash Equivalents At Carrying Value | 49382000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Common Stock Par Or Stated Value Per Share | 2.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Common Stock Shares Authorized | 200000000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Common Stock Shares Outstanding | 77199000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Common Stock Shares Outstanding | 77220000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Common Stock Value | 154398000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Cost Of Revenue | 1751393000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Earnings Per Share Basic | -0.3200 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Earnings Per Share Diluted | -0.3200 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Increase Decrease In Inventories | 274589000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Intangible Assets Net Excluding Goodwill | 83000000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20240331 | Interest Expense | 35655000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Interest Paid Net | 27487000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Liabilities | 4069792000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Long Term Debt And Capital Lease Obligations | 1897515000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 5957000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001558370-25-006964 | 20241231 | Other Liabilities Noncurrent | 101025000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Operating Income Expense Net | -266000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Repayments Of Long Term Debt | 0.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2612680000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 62070000.0000 | USD | 1 | us-gaap/2023 | Geographical= Non Us; | ||
| 0001558370-25-006964 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2632048000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 51332000.0000 | USD | 1 | us-gaap/2023 | Geographical= Non Us; | ||
| 0001558370-25-006964 | 20250331 | Selling General And Administrative Expense | 258835000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Share Based Compensation | 6866000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Share Based Compensation | 4068000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | 389845000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | -46220000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | 438587000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006964 | 20250331 | Stock Repurchased And Retired During Period Shares | 200000.0000 | shares | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Stock Repurchased And Retired During Period Value | 346000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20240331 | Value Of Shares Adjusted For Share Based Compensation | 4402000.0000 | USD | 1 | 0001558370-25-006964 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006964 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 270794000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Common Stock Shares Issued | 77199000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Common Stock Shares Outstanding | 77199000.0000 | shares | 0 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20240331 | Cost Of Revenue | 338251000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Cost Of Revenue | 2106035000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Depreciation Depletion And Amortization | 36465000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20250331 | Depreciation Depletion And Amortization | 61153000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Depreciation Depletion And Amortization | 10833000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20250331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 542000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Goodwill | 1228140000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20250331 | Goodwill | 103791000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -27112000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Increase Decrease In Inventories | 35412000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Intangible Assets Net Excluding Goodwill | 112786000.0000 | USD | 0 | us-gaap/2023 | Finite Lived Intangible Assets By Major Class= Trade Names; | ||
| 0001558370-25-006964 | 20250331 | Intangible Assets Net Excluding Goodwill | 285086000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Long Term Debt And Capital Lease Obligations | 1808047000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Long Term Debt And Capital Lease Obligations | 1760451000.0000 | USD | 0 | us-gaap/2023 | Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001558370-25-006964 | 20250331 | Operating Income Loss | 61294000.0000 | USD | 1 | us-gaap/2023 | Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Operating Lease Right Of Use Asset | 355627000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Operating Lease Right Of Use Asset | 383111000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent | -235000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | 1412000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -11619000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Liabilities Noncurrent | 87376000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Operating Income Expense Net | -181000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Payments For Software | 3411000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Proceeds From Sale Of Property Plant And Equipment | 16884000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20231231 | Retained Earnings Accumulated Deficit | 21000000.0000 | USD | 0 | us-gaap/2023 | Restatement= Revision Of Prior Period Error Correction Adjustment; | ||
| 0001558370-25-006964 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 637843000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1974837000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2632048000.0000 | USD | 1 | us-gaap/2023 | Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Selling General And Administrative Expense | 253532000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Stockholders Equity | -4880000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | 4525000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | -48099000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | 27159000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | 2906000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001558370-25-006964 | 20250331 | Stock Issued During Period Value Share Based Compensation | 5580000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006964 | 20250331 | Stock Repurchased And Retired During Period Shares | 173000.0000 | shares | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20250331 | Stock Repurchased And Retired During Period Value | 1503000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Stock Repurchased And Retired During Period Value | 1157000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20250331 | Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 582286000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Assets | 4796988000.0000 | USD | 0 | us-gaap/2023 | Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 49382000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | -44211000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006964 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2023 | ||||
| 0001558370-25-006964 | 20250331 | Common Stock Shares Issued | 77220000.0000 | shares | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Cost Of Revenue | 354642000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Earnings Per Share Diluted | -0.2900 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -618000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Income Taxes Paid Net | 2365000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Increase Decrease In Accounts And Notes Receivable | 74963000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Increase Decrease In Accounts And Notes Receivable | -111613000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Intangible Assets Net Excluding Goodwill | 298726000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Intangible Assets Net Excluding Goodwill | 162588000.0000 | USD | 0 | us-gaap/2023 | Finite Lived Intangible Assets By Major Class= Customer Relationships; | ||
| 0001558370-25-006964 | 20250331 | Intangible Assets Net Excluding Goodwill | 202000000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20250331 | Intangible Assets Net Excluding Goodwill | 18558000.0000 | USD | 0 | us-gaap/2023 | Finite Lived Intangible Assets By Major Class= Other Intangible Assets; | ||
| 0001558370-25-006964 | 20250331 | Intangible Assets Net Excluding Goodwill | 107895000.0000 | USD | 0 | us-gaap/2023 | Finite Lived Intangible Assets By Major Class= Trade Names; | ||
| 0001558370-25-006964 | 20241231 | Inventory Net | 1131879000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Inventory Net | 1408539000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Long Term Debt And Capital Lease Obligations | 1808047000.0000 | USD | 0 | us-gaap/2023 | Fair Value By Measurement Basis= Carrying Reported Amount Fair Value Disclosure; | ||
| 0001558370-25-006964 | 20250331 | Long Term Debt And Capital Lease Obligations | 1757371000.0000 | USD | 0 | us-gaap/2023 | Fair Value By Measurement Basis= Estimate Of Fair Value Fair Value Disclosure; | ||
| 0001558370-25-006964 | 20250331 | Net Income Loss | -24982000.0000 | USD | 1 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20240331 | Operating Income Loss | 9696000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Operating Income Loss | 45879000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20241231 | Operating Lease Liability Noncurrent | 286212000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent | -795000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -13266000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 5133000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Liabilities Current | 442144000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Operating Income Expense Net | -2637000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Payments For Proceeds From Other Investing Activities | 2000000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Proceeds From Long Term Lines Of Credit | 776984000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Proceeds From Payments For Other Financing Activities | -7755000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Share Based Compensation | 4769000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | 434185000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | 586364000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 509347000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Acquisition Related Charges And Intangible Amortization | 29674000.0000 | USD | 1 | 0001558370-25-006964 | Consolidation Items= Material Reconciling Items; | ||
| 0001558370-25-006964 | 20241231 | Assets | 4656156000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Assets | 2630037000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20240331 | Business Exit Costs1 | 27356000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Common Stock Par Or Stated Value Per Share | 2.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Common Stock Value | 154439000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Earnings Per Share Basic | -0.2900 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20241231 | Goodwill | 1228140000.0000 | USD | 0 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20250331 | Goodwill | 1331931000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Gross Profit | 535529000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -35074000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Income Taxes Paid Net | 125000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Increase Decrease In Accounts Payable Trade | 52926000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Increase Decrease In Other Operating Capital Net | 39617000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Interest Expense | 33959000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Net Cash Provided By Used In Financing Activities | 53320000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Net Income Loss | -21886000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Nonoperating Income Expense | -1153000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Operating Lease Liability Noncurrent | 324032000.0000 | USD | 0 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 5957000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20231231 | Other Liabilities Current | 1600000.0000 | USD | 0 | us-gaap/2023 | Restatement= Revision Of Prior Period Error Correction Adjustment; | ||
| 0001558370-25-006964 | 20250331 | Other Noncash Income Expense | -760000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Payments For Software | 8977000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Proceeds From Accounts Receivable Financing Agreement | 205000000.0000 | USD | 1 | 0001558370-25-006964 | |||
| 0001558370-25-006964 | 20240331 | Proceeds From Sale Of Property Plant And Equipment | 49538000.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20240331 | Repayments Of Long Term Lines Of Credit | 0.0000 | USD | 1 | us-gaap/2023 | |||
| 0001558370-25-006964 | 20250331 | Selling General And Administrative Expense | 203517000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Products Healthcare Services; Consolidation Items= Operating Segments; | ||
| 0001558370-25-006964 | 20250331 | Share Based Compensation | 2530000.0000 | USD | 1 | us-gaap/2023 | Business Segments= Patient Direct; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | 6251000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Gain Loss Net Cash Flow Hedge Parent; | ||
| 0001558370-25-006964 | 20231231 | Stockholders Equity | -32954000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001558370-25-006964 | 20241231 | Stockholders Equity | -5770000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | -4975000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Accumulated Defined Benefit Plans Adjustment; | ||
| 0001558370-25-006964 | 20250331 | Stockholders Equity | 1020000.0000 | USD | 0 | us-gaap/2023 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006964 | 20250331 | Stock Issued During Period Shares Share Based Compensation | 194000.0000 | shares | 1 | us-gaap/2023 | Equity Components= Common Stock; | ||
| 0001558370-25-006964 | 20250331 | Stock Issued During Period Value Share Based Compensation | 5967000.0000 | USD | 1 | us-gaap/2023 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Allowance For Doubtful Accounts Receivable Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Accounts Receivable, Allowance for Credit Loss, Current | Amount of allowance for credit loss on accounts receivable, classified as current. |
| Operating Lease Liability Noncurrent | us-gaap/2023 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2023 | 0 | 0 | monetary | I | C | Accumulated other comprehensive income | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2023 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Deferred Income Tax Liabilities Net | us-gaap/2023 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2023 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Increase Decrease In Accounts And Notes Receivable | us-gaap/2023 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts and Notes Receivable | The increase (decrease) during the reporting period of the sum of amounts due within one year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for outstanding loans. |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | 0 | 0 | monetary | D | D | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations | Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2023 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | Amount after tax of other comprehensive income (loss) attributable to parent entity. |
| Interest Paid Net | us-gaap/2023 | 0 | 0 | monetary | D | C | Cash paid for interest | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Operating Income Loss | us-gaap/2023 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Assets Noncurrent | us-gaap/2023 | 0 | 0 | monetary | I | D | Other assets | Amount of noncurrent assets classified as other. |
| Additional Paid In Capital Common Stock | us-gaap/2023 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2023 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Acquisition Related Charges And Intangible Amortization | 0001558370-25-006964 | 1 | 0 | monetary | D | D | Acquisition Related Charges and Intangible Amortization | The amount of acquisition-related charges and intangible amortization incurred during the period. |
| Common Stock Value | us-gaap/2023 | 0 | 0 | monetary | I | C | Common stock, $0.001 par value; 100,000,000 and 50,000,000 shares authorized as of December 31, 2022 and December 31, 2021; 15,193,587 and 13,466,603 shares issued as of December 31, 2022 and December 31, 2021, respectively; 15,166,596 and 13,439,612 shares outstanding as of December 31, 2022 and December 31, 2021, respectively | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Earnings Per Share Basic | us-gaap/2023 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Interest Expense | us-gaap/2023 | 0 | 0 | monetary | D | D | Interest Expense | Amount of the cost of borrowed funds accounted for as interest expense. |
| Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent | us-gaap/2023 | 0 | 0 | monetary | D | D | Other Comprehensive (Income) Loss, Defined Benefit Plan, before Tax, after Reclassification Adjustment, Attributable to Parent | Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive (income) loss for defined benefit plan, attributable to parent entity. |
| Common Stock Shares Issued | us-gaap/2023 | 0 | 0 | shares | I | Common stock, shares issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Income Tax Expense Benefit | us-gaap/2023 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Liabilities And Stockholders Equity | us-gaap/2023 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2023 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Nonoperating Income Expense | us-gaap/2023 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Goodwill | us-gaap/2023 | 0 | 0 | monetary | I | D | Goodwill | Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. |
| Increase Decrease In Inventories | us-gaap/2023 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Other Operating Income Expense Net | us-gaap/2023 | 0 | 0 | monetary | D | C | Other Operating Income (Expense), Net | The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations. |
| Payments For Proceeds From Other Investing Activities | us-gaap/2023 | 0 | 0 | monetary | D | C | Payments for (Proceeds from) Other Investing Activities | Amount of cash (inflow) outflow from investing activities classified as other. |
| Earnings Per Share Diluted | us-gaap/2023 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Repayments Of Accounts Receivable Financing Agreement | 0001558370-25-006964 | 1 | 0 | monetary | D | C | Repayments of Accounts Receivable Financing Agreement | The amount of repayments of accounts receivable financing agreement. |
| Assets Current | us-gaap/2023 | 0 | 0 | monetary | I | D | Assets, Current | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. |
| Common Stock Shares Outstanding | us-gaap/2023 | 0 | 0 | shares | I | Common stock, shares outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Income Taxes Paid Net | us-gaap/2023 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes. |
| Increase Decrease In Accounts Payable Trade | us-gaap/2023 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable, Trade | Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2023 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Gross Profit | us-gaap/2023 | 0 | 0 | monetary | D | C | GROSS MARGIN | Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. |
| Increase Decrease In Other Operating Capital Net | us-gaap/2023 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Operating Assets and Liabilities, Net | Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. |
| Repayments Of Long Term Debt | us-gaap/2023 | 0 | 0 | monetary | D | C | Repayments of Long-Term Debt | The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. |
| Operating Lease Right Of Use Asset | us-gaap/2023 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2023 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2023 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Selling General And Administrative Expense | us-gaap/2023 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Net Income Loss | us-gaap/2023 | 0 | 0 | monetary | D | C | Net loss | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2023 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Repayments Of Long Term Lines Of Credit | us-gaap/2023 | 0 | 0 | monetary | D | C | Repayments of Long-Term Lines of Credit | The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Proceeds From Accounts Receivable Financing Agreement | 0001558370-25-006964 | 1 | 0 | monetary | D | D | Proceeds from Accounts Receivable Financing Agreement | The amount of proceeds from accounts receivable financing agreement. |
| Proceeds From Long Term Lines Of Credit | us-gaap/2023 | 0 | 0 | monetary | D | D | Proceeds from Long-Term Lines of Credit | The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. |
| Proceeds From Sale Of Property Plant And Equipment | us-gaap/2023 | 0 | 0 | monetary | D | D | Proceeds from Sale of Property, Plant, and Equipment | The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Assets | us-gaap/2023 | 0 | 0 | monetary | I | D | Assets | Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. |
| Common Stock Shares Authorized | us-gaap/2023 | 0 | 0 | shares | I | Common stock, shares authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Retained Earnings Accumulated Deficit | us-gaap/2023 | 0 | 0 | monetary | I | C | Accumulated deficit | Amount of accumulated undistributed earnings (deficit). |
| Other Liabilities Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Other Liabilities, Current | Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer. |
| Shares Adjusted For Share Based Compensation | 0001558370-25-006964 | 1 | 0 | shares | D | Shares Adjusted For Share Based Compensation | Number of shares adjusted for share based compensation. | |
| Commitments And Contingencies | us-gaap/2023 | 0 | 0 | monetary | I | C | Commitments and contingencies (Note 14) | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Cost Of Revenue | us-gaap/2023 | 0 | 0 | monetary | D | D | COST OF SALES | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Depreciation Depletion And Amortization | us-gaap/2023 | 0 | 0 | monetary | D | D | Depreciation expense | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Business Exit Costs1 | us-gaap/2023 | 0 | 0 | monetary | D | D | Business Exit Costs | Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. |
| Deferred Income Taxes And Tax Credits | us-gaap/2023 | 0 | 0 | monetary | D | D | Deferred Income Taxes and Tax Credits | Amount of deferred income tax expense (benefit) and income tax credits. |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | us-gaap/2023 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent | Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent. |
| Long Term Debt And Capital Lease Obligations | us-gaap/2023 | 0 | 0 | monetary | I | C | Long-Term Debt and Lease Obligation | Amount of long-term debt and lease obligation, classified as noncurrent. |
| Payments For Software | us-gaap/2023 | 0 | 0 | monetary | D | C | Payments for Software | The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization. |
| Other Assets Current | us-gaap/2023 | 0 | 0 | monetary | I | D | Other Assets, Current | Amount of current assets classified as other. |
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2023 | 0 | 0 | monetary | I | D | Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization | Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset. |
| Stock Repurchased And Retired During Period Value | us-gaap/2023 | 0 | 0 | monetary | D | D | Stock Repurchased and Retired During Period, Value | Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). |
| Increase Decrease In Operating Lease Right Of Use Assets And Operating Lease Liability | 0001558370-25-006964 | 1 | 0 | monetary | D | C | Increase (Decrease) In Operating Lease, Right Of Use, Assets And Operating Lease, Liability | Increase (Decrease) In Operating Lease, Right Of Use, Assets And Operating Lease, Liability |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | us-gaap/2023 | 0 | 0 | monetary | I | C | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2023 | 0 | 0 | perShare | I | Common stock, par value | Face amount or stated value per share of common stock. | |
| Employee Related Liabilities Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Accrued payroll and benefits | Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Liabilities | us-gaap/2023 | 0 | 0 | monetary | I | C | Liabilities | Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. |
| Inventory Net | us-gaap/2023 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Share Based Compensation | us-gaap/2023 | 0 | 0 | monetary | D | D | Share-based compensation | Amount of noncash expense for share-based payment arrangement. |
| Other Noncash Income Expense | us-gaap/2023 | 0 | 0 | monetary | D | C | Other Noncash Income (Expense) | Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. |
| Stock Issued During Period Shares Share Based Compensation | us-gaap/2023 | 0 | 0 | shares | D | Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture | Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP). | |
| Stock Issued During Period Value Share Based Compensation | us-gaap/2023 | 0 | 0 | monetary | D | C | Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture | Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). |
| Additions To Property And Equipment Exclude Purchases Remain Unpaid | 0001558370-25-006964 | 1 | 0 | monetary | I | C | Additions To Property And Equipment Exclude Purchases Remain Unpaid | Additions To Property And Equipment Exclude Purchases Remain Unpaid |
| Accounts And Notes Receivable Net | us-gaap/2023 | 0 | 0 | monetary | I | D | Accounts and Financing Receivable, after Allowance for Credit Loss | Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable. |
| Proceeds From Payments For Other Financing Activities | us-gaap/2023 | 0 | 0 | monetary | D | D | Proceeds from (Payments for) Other Financing Activities | Amount of cash inflow (outflow) from financing activities classified as other. |
| Other Liabilities Noncurrent | us-gaap/2023 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Gain Loss On Sale Of Property Plant Equipment | us-gaap/2023 | 0 | 0 | monetary | D | C | Gain (Loss) on Disposition of Property Plant Equipment | Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. |
| Payments For Repurchase Of Common Stock | us-gaap/2023 | 0 | 0 | monetary | D | C | Payments for Repurchase of Common Stock | The cash outflow to reacquire common stock during the period. |
| Value Of Shares Adjusted For Share Based Compensation | 0001558370-25-006964 | 1 | 0 | monetary | D | C | Value Of Shares Adjusted For Share Based Compensation | Amount of shares adjusted during the period for share based compensation. |
| Liabilities Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Accounts Payable Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Accounts payable | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Net Cash Provided By Used In Investing Activities | us-gaap/2023 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Stockholders Equity | us-gaap/2023 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Comprehensive Income Net Of Tax | us-gaap/2023 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Long Term Debt Current | us-gaap/2023 | 0 | 0 | monetary | I | C | Long-Term Debt, Current Maturities | Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. |
| Stock Repurchased And Retired During Period Shares | us-gaap/2023 | 0 | 0 | shares | D | Stock Repurchased and Retired During Period, Shares | Number of shares that have been repurchased and retired during the period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-006964 | 2 | 1 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2023 | Net revenue | 0 |
| 0001558370-25-006964 | 2 | 3 | IS | 0 | H | Cost Of Revenue | us-gaap/2023 | Cost of goods sold | 0 |
| 0001558370-25-006964 | 2 | 4 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2023 | Distribution, selling and administrative expenses | 0 |
| 0001558370-25-006964 | 2 | 5 | IS | 0 | H | Acquisition Related Charges And Intangible Amortization | 0001558370-25-006964 | Acquisition-related charges and intangible amortization | 0 |
| 0001558370-25-006964 | 2 | 6 | IS | 0 | H | Business Exit Costs1 | us-gaap/2023 | Exit and realignment charges, net | 0 |
| 0001558370-25-006964 | 2 | 7 | IS | 0 | H | Gross Profit | us-gaap/2023 | Gross profit | 0 |
| 0001558370-25-006964 | 2 | 8 | IS | 0 | H | Other Operating Income Expense Net | us-gaap/2023 | Other operating expense (income), net | 1 |
| 0001558370-25-006964 | 2 | 9 | IS | 0 | H | Operating Income Loss | us-gaap/2023 | Operating income | 0 |
| 0001558370-25-006964 | 2 | 10 | IS | 0 | H | Interest Expense | us-gaap/2023 | Interest expense, net | 0 |
| 0001558370-25-006964 | 2 | 11 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2023 | Other expense, net | 1 |
| 0001558370-25-006964 | 2 | 12 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2023 | Loss before income taxes | 0 |
| 0001558370-25-006964 | 2 | 13 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2023 | Income tax benefit | 0 |
| 0001558370-25-006964 | 2 | 14 | IS | 0 | H | Net Income Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-006964 | 2 | 16 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2023 | Net loss per common share Basic (in dollars per share) | 0 |
| 0001558370-25-006964 | 2 | 18 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2023 | Net loss per common share Diluted (in dollars per share) | 0 |
| 0001558370-25-006964 | 3 | 1 | CI | 0 | H | Net Income Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-006964 | 3 | 3 | CI | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2023 | Currency translation adjustments | 0 |
| 0001558370-25-006964 | 3 | 4 | CI | 0 | H | Other Comprehensive Income Defined Benefit Plans Adjustment Before Tax Portion Attributable To Parent | us-gaap/2023 | Change in unrecognized net periodic pension costs | 1 |
| 0001558370-25-006964 | 3 | 5 | CI | 0 | H | Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Parent | us-gaap/2023 | Change in gains and losses on derivative instruments | 0 |
| 0001558370-25-006964 | 3 | 6 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2023 | Total other comprehensive income (loss), net of tax | 0 |
| 0001558370-25-006964 | 3 | 7 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2023 | Comprehensive loss | 0 |
| 0001558370-25-006964 | 4 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2023 | Cash and cash equivalents | 0 |
| 0001558370-25-006964 | 4 | 4 | BS | 0 | H | Accounts And Notes Receivable Net | us-gaap/2023 | Accounts receivable, net of allowances of $6,371 and $6,238 | 0 |
| 0001558370-25-006964 | 4 | 5 | BS | 0 | H | Inventory Net | us-gaap/2023 | Merchandise inventories | 0 |
| 0001558370-25-006964 | 4 | 6 | BS | 0 | H | Other Assets Current | us-gaap/2023 | Other current assets | 0 |
| 0001558370-25-006964 | 4 | 7 | BS | 0 | H | Assets Current | us-gaap/2023 | Total current assets | 0 |
| 0001558370-25-006964 | 4 | 8 | BS | 0 | H | Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | us-gaap/2023 | Property and equipment, net of accumulated depreciation and amortization of $582,286 and $565,119 | 0 |
| 0001558370-25-006964 | 4 | 9 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2023 | Operating lease assets | 0 |
| 0001558370-25-006964 | 4 | 10 | BS | 0 | H | Goodwill | us-gaap/2023 | Goodwill | 0 |
| 0001558370-25-006964 | 4 | 11 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2023 | Intangible assets, net | 0 |
| 0001558370-25-006964 | 4 | 12 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2023 | Other assets, net | 0 |
| 0001558370-25-006964 | 4 | 13 | BS | 0 | H | Assets | us-gaap/2023 | Total assets | 0 |
| 0001558370-25-006964 | 4 | 16 | BS | 0 | H | Accounts Payable Current | us-gaap/2023 | Accounts payable | 0 |
| 0001558370-25-006964 | 4 | 17 | BS | 0 | H | Employee Related Liabilities Current | us-gaap/2023 | Accrued payroll and related liabilities | 0 |
| 0001558370-25-006964 | 4 | 18 | BS | 0 | H | Long Term Debt Current | us-gaap/2023 | Current portion of long-term debt | 0 |
| 0001558370-25-006964 | 4 | 19 | BS | 0 | H | Other Liabilities Current | us-gaap/2023 | Other current liabilities | 0 |
| 0001558370-25-006964 | 4 | 20 | BS | 0 | H | Liabilities Current | us-gaap/2023 | Total current liabilities | 0 |
| 0001558370-25-006964 | 4 | 21 | BS | 0 | H | Long Term Debt And Capital Lease Obligations | us-gaap/2023 | Long-term debt, excluding current portion | 0 |
| 0001558370-25-006964 | 4 | 22 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2023 | Operating lease liabilities, excluding current portion | 0 |
| 0001558370-25-006964 | 4 | 23 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2023 | Deferred income taxes, net | 0 |
| 0001558370-25-006964 | 4 | 24 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2023 | Other liabilities | 0 |
| 0001558370-25-006964 | 4 | 25 | BS | 0 | H | Liabilities | us-gaap/2023 | Total liabilities | 0 |
| 0001558370-25-006964 | 4 | 26 | BS | 0 | H | Commitments And Contingencies | us-gaap/2023 | Commitments and contingencies | 0 |
| 0001558370-25-006964 | 4 | 28 | BS | 0 | H | Common Stock Value | us-gaap/2023 | Common stock, par value $2 per share; authorized - 200,000 shares; issued and outstanding - 77,220 shares and 77,199 shares | 0 |
| 0001558370-25-006964 | 4 | 29 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2023 | Paid-in capital | 0 |
| 0001558370-25-006964 | 4 | 30 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2023 | Retained earnings | 0 |
| 0001558370-25-006964 | 4 | 31 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2023 | Accumulated other comprehensive loss | 0 |
| 0001558370-25-006964 | 4 | 32 | BS | 0 | H | Stockholders Equity | us-gaap/2023 | Total equity | 0 |
| 0001558370-25-006964 | 4 | 33 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2023 | Total liabilities and equity | 0 |
| 0001558370-25-006964 | 5 | 1 | BS | 1 | H | Allowance For Doubtful Accounts Receivable Current | us-gaap/2023 | Allowances for losses on accounts receivable | 0 |
| 0001558370-25-006964 | 5 | 2 | BS | 1 | H | Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | us-gaap/2023 | Accumulated depreciation and amortization | 0 |
| 0001558370-25-006964 | 5 | 3 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2023 | Common stock, par value (in dollar per share) | 0 |
| 0001558370-25-006964 | 5 | 4 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2023 | Common stock, authorized (shares) | 0 |
| 0001558370-25-006964 | 5 | 5 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2023 | Common stock, issued (shares) | 0 |
| 0001558370-25-006964 | 5 | 6 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2023 | Commons stock, outstanding (shares) | 0 |
| 0001558370-25-006964 | 6 | 2 | CF | 0 | H | Net Income Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-006964 | 6 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2023 | Depreciation and amortization | 0 |
| 0001558370-25-006964 | 6 | 5 | CF | 0 | H | Share Based Compensation | us-gaap/2023 | Share-based compensation expense | 0 |
| 0001558370-25-006964 | 6 | 6 | CF | 0 | H | Deferred Income Taxes And Tax Credits | us-gaap/2023 | Deferred income tax benefit | 0 |
| 0001558370-25-006964 | 6 | 7 | CF | 0 | H | Increase Decrease In Operating Lease Right Of Use Assets And Operating Lease Liability | 0001558370-25-006964 | Changes in operating lease right-of-use assets and lease liabilities | 1 |
| 0001558370-25-006964 | 6 | 8 | CF | 0 | H | Gain Loss On Sale Of Property Plant Equipment | us-gaap/2023 | Gain from sale and dispositions of patient service equipment, property and equipment | 1 |
| 0001558370-25-006964 | 6 | 10 | CF | 0 | H | Increase Decrease In Accounts And Notes Receivable | us-gaap/2023 | Accounts receivable, net | 1 |
| 0001558370-25-006964 | 6 | 11 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2023 | Merchandise inventories | 1 |
| 0001558370-25-006964 | 6 | 12 | CF | 0 | H | Increase Decrease In Accounts Payable Trade | us-gaap/2023 | Accounts payable | 0 |
| 0001558370-25-006964 | 6 | 13 | CF | 0 | H | Increase Decrease In Other Operating Capital Net | us-gaap/2023 | Net change in other assets and liabilities | 1 |
| 0001558370-25-006964 | 6 | 14 | CF | 0 | H | Other Noncash Income Expense | us-gaap/2023 | Other, net | 1 |
| 0001558370-25-006964 | 6 | 15 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2023 | Cash used for operating activities | 0 |
| 0001558370-25-006964 | 6 | 17 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2023 | Acquisition, net of cash acquired | 1 |
| 0001558370-25-006964 | 6 | 18 | CF | 0 | H | Proceeds From Sale Of Property Plant And Equipment | us-gaap/2023 | Proceeds from sale of property and equipment | 0 |
| 0001558370-25-006964 | 6 | 19 | CF | 0 | H | Payments For Software | us-gaap/2023 | Additions to computer software | 1 |
| 0001558370-25-006964 | 6 | 20 | CF | 0 | H | Payments For Proceeds From Other Investing Activities | us-gaap/2023 | Other, net | 1 |
| 0001558370-25-006964 | 6 | 21 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2023 | Cash used for investing activities | 0 |
| 0001558370-25-006964 | 6 | 23 | CF | 0 | H | Proceeds From Accounts Receivable Financing Agreement | 0001558370-25-006964 | Borrowings under amended Receivables Financing Agreement | 0 |
| 0001558370-25-006964 | 6 | 24 | CF | 0 | H | Repayments Of Accounts Receivable Financing Agreement | 0001558370-25-006964 | Repayments under amended Receivables Financing Agreement | 1 |
| 0001558370-25-006964 | 6 | 25 | CF | 0 | H | Proceeds From Long Term Lines Of Credit | us-gaap/2023 | Borrowings under Revolving Credit Facility | 0 |
| 0001558370-25-006964 | 6 | 26 | CF | 0 | H | Repayments Of Long Term Lines Of Credit | us-gaap/2023 | Repayments under Revolving Credit Facility | 1 |
| 0001558370-25-006964 | 6 | 27 | CF | 0 | H | Repayments Of Long Term Debt | us-gaap/2023 | Repayments of term loans | 1 |
| 0001558370-25-006964 | 6 | 28 | CF | 0 | H | Payments For Repurchase Of Common Stock | us-gaap/2023 | Repurchase of common stock | 1 |
| 0001558370-25-006964 | 6 | 29 | CF | 0 | H | Proceeds From Payments For Other Financing Activities | us-gaap/2023 | Other, net | 0 |
| 0001558370-25-006964 | 6 | 30 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2023 | Cash provided by financing activities | 0 |
| 0001558370-25-006964 | 6 | 31 | CF | 0 | H | Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 |
| 0001558370-25-006964 | 6 | 32 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2023 | Net increase (decrease) in cash, cash equivalents and restricted cash | 0 |
| 0001558370-25-006964 | 6 | 33 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | Cash, cash equivalents and restricted cash at beginning of period | 0 |
| 0001558370-25-006964 | 6 | 34 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2023 | Cash, cash equivalents and restricted cash at end of period | 0 |
| 0001558370-25-006964 | 6 | 36 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2023 | Income taxes paid, net | 0 |
| 0001558370-25-006964 | 6 | 37 | CF | 0 | H | Interest Paid Net | us-gaap/2023 | Interest paid | 0 |
| 0001558370-25-006964 | 6 | 39 | CF | 0 | H | Additions To Property And Equipment Exclude Purchases Remain Unpaid | 0001558370-25-006964 | Unpaid purchases of property and equipment and computer software at end of period | 0 |
| 0001558370-25-006964 | 7 | 10 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2023 | Beginning balance (in shares) | 0 |
| 0001558370-25-006964 | 7 | 11 | EQ | 0 | H | Stockholders Equity | us-gaap/2023 | Beginning balance | 0 |
| 0001558370-25-006964 | 7 | 12 | EQ | 0 | H | Net Income Loss | us-gaap/2023 | Net loss | 0 |
| 0001558370-25-006964 | 7 | 13 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2023 | Other comprehensive loss | 0 |
| 0001558370-25-006964 | 7 | 14 | EQ | 0 | H | Stock Issued During Period Shares Share Based Compensation | us-gaap/2023 | Share-based compensation expense, exercises and other (in shares) | 0 |
| 0001558370-25-006964 | 7 | 15 | EQ | 0 | H | Stock Issued During Period Value Share Based Compensation | us-gaap/2023 | Share-based compensation expense, exercises and other | 0 |
| 0001558370-25-006964 | 7 | 16 | EQ | 0 | H | Stock Repurchased And Retired During Period Value | us-gaap/2023 | Shares repurchased and retired | 1 |
| 0001558370-25-006964 | 7 | 17 | EQ | 0 | H | Stock Repurchased And Retired During Period Shares | us-gaap/2023 | Shares repurchased and retired (in shares) | 0 |
| 0001558370-25-006964 | 7 | 18 | EQ | 0 | H | Shares Adjusted For Share Based Compensation | 0001558370-25-006964 | Share-based compensation expense, exercises and other (in shares) | 0 |
| 0001558370-25-006964 | 7 | 19 | EQ | 0 | H | Value Of Shares Adjusted For Share Based Compensation | 0001558370-25-006964 | Share-based compensation expense, exercises and other | 0 |
| 0001558370-25-006964 | 7 | 20 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2023 | Ending balance (in shares) | 0 |
| 0001558370-25-006964 | 7 | 21 | EQ | 0 | H | Stockholders Equity | us-gaap/2023 | Ending balance | 0 |
| 0001558370-25-006964 | 8 | 1 | EQ | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2023 | Common stock, par value (in dollar per share) | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |